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Signaling by the Wnt family of secreted glycolipoproteins via the transcriptional coactivator b-catenin
controls embryonic development and adult homeostasis. Here we review recent progress in this so-called
canonical Wnt signaling pathway. We discuss Wnt ligands, agonists, and antagonists, and their interactions
withWnt receptors. We also dissect critical events that regulate b-catenin stability, fromWnt receptors to the
cytoplasmic b-catenin destruction complex, and nuclear machinery that mediates b-catenin-dependent
transcription. Finally, we highlight some key aspects of Wnt/b-catenin signaling in human diseases including
congenital malformations, cancer, and osteoporosis, and discuss potential therapeutic implications.Introduction
Signaling by the Wnt family of secreted glycolipoproteins is one
of the fundamental mechanisms that direct cell proliferation, cell
polarity, and cell fate determination during embryonic develop-
ment and tissue homeostasis (Logan and Nusse, 2004). As
a result, mutations in the Wnt pathway are often linked to human
birth defects, cancer, and other diseases (Clevers, 2006). A crit-
ical and heavily studied Wnt pathway is the canonical Wnt
pathway, which functions by regulating the amount of the tran-
scriptional coactivator b-catenin, which controls key develop-
mental gene expression programs. This review focuses on our
current understanding of Wnt/b-catenin signaling, drawing
mainly from genetic, developmental, and biochemical analyses
inDrosophila, Xenopus, mouse, and human. For a more compre-
hensive and historic perspective, we refer readers to earlier
reviews (Clevers, 2006; Logan and Nusse, 2004) and the Wnt
homepage (www.stanford.edu/rnusse/wntwindow.html). The
nematode Caenorhabditis elegans exhibits similar but also
divergent Wnt/b-catenin pathways, which have been covered
previously (Mizumoto and Sawa, 2007) and are covered in the
accompanying review by Phillips and Kimble (2009) in this issue
of Developmental Cell. Wnt also activates a number of nonca-
nonical signaling pathways that are independent of b-catenin
and have been recently reviewed as well (Seifert and Mlodzik,
2007; Wang and Nathans, 2007).
The central logic of Wnt/b-catenin signaling has emerged from
two decades of studies (Figure 1). In the absence of Wnt, cyto-
plasmic b-catenin protein is constantly degraded by the action
of the Axin complex, which is composed of the scaffolding
protein Axin, the tumor suppressor adenomatous polyposis coli
gene product (APC), casein kinase 1 (CK1), and glycogen syn-
thase kinase 3 (GSK3). CK1 and GSK3 sequentially phosphory-
late the amino terminal region of b-catenin, resulting in b-catenin
recognition by b-Trcp, an E3 ubiquitin ligase subunit, and subse-
quent b-catenin ubiquitination and proteasomal degradation (He
et al., 2004). This continual elimination of b-catenin prevents
b-catenin from reaching the nucleus, and Wnt target genes are
thereby repressed by the DNA-bound T cell factor/lymphoid
enhancer factor (TCF/LEF) family of proteins (Figure 1A). TheWnt/b-catenin pathway is activated when a Wnt ligand binds to
the seven-pass transmembrane Frizzled (Fz or Fzd) receptor
and its coreceptor, low-density lipoprotein receptor-related
protein 6 (LRP6), or its close relative LRP5. The formation of
a likely Wnt-Fz-LRP6 complex, together with the recruitment of
the scaffolding protein Dishevelled (Dvl), results in LRP6 phos-
phorylation and activation and the recruitment of the Axin
complex to the receptors. These events lead to inhibition of
Axin-mediated b-catenin phosphorylation and thereby to the
stabilization of b-catenin, which accumulates and travels to the
nucleus to form complexes with TCF/LEF and activates Wnt
target gene expression (Figure 1B).
Wnt Ligands and Biogenesis
Wnts are conserved in all metazoan animals. In mammals,
complexity and specificity in Wnt signaling are in part achieved
through 19 Wnt ligands, which are cysteine-rich proteins of
approxiamately 350–400 amino acids that contain an N-terminal
signal peptide for secretion. Murine WNT3A was the first purified
and biochemically characterized Wnt protein (Willert et al., 2003),
owing to its relatively efficient secretion (in contrast to most other
Wnt proteins). In addition to N-linked glycosylation, which is
required for WNT3A secretion (Komekado et al., 2007), WNT3A
undergoes two types of lipid modifications that likely account
for the hydrophobicity and poor solubility of Wnt proteins (Haus-
mann et al., 2007). The first reported lipididation was the addition
of palmitate to cysteine 77 (Willert et al., 2003). Its mutation had
minimal effect on WNT3A secretion but diminished the ability of
WNT3A to activate b-catenin signaling (Galli et al., 2007; Kome-
kado et al., 2007; Willert et al., 2003). The second identified
lipididation was a palmitoleoyl attached to serine 209, and its
mutation resulted in WNT3A accumulation in the endoplasmic
reticulum (ER) and a failure in secretion (Takada et al., 2006).
DrosophilaWingless (Wg) is the Wnt molecule most investigated
in vivo (Hausmann et al., 2007). These studies plus work in nema-
todes have identified genes that regulate Wnt biogenesis and
secretion. Porcupine encodes a multipass transmembrane ER
protein that contains an O-acyl transferase domain, suggesting
a role in Wg lipid modification (Hausmann et al., 2007). PorcupineDevelopmental Cell 17, July 21, 2009 ª2009 Elsevier Inc. 9
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ReviewFigure 1. Overview of Wnt/b-Catenin Signaling
(A) In the absence of Wnt, cytoplasmic b-catenin forms a complex with Axin, APC, GSK3, and CK1, and is phosphorylated by CK1 (blue) and subsequently by
GSK3 (yellow). Phosphorylated b-catenin is recognized by the E3 ubiquitin ligase b-Trcp, which targets b-catenin for proteosomal degradation. Wnt target genes
are repressed by TCF-TLE/Groucho and histone deacetylases (HDAC).
(B) In the presence of Wnt ligand, a receptor complex forms between Fz and LRP5/6. Dvl recruitment by Fz leads to LRP5/6 phosphorylation and Axin recruitment.
This disrupts Axin-mediated phosphorylation/degradation of b-catenin, allowing b-catenin to accumulate in the nucleus where it serves as a coactivator for TCF
to activate Wnt-responsive genes.deficiency results in Wg and WNT3A accumulation in the ER and
diminished WNT3A palmitoleoylation at serine 209 (Takada et al.,
2006), suggesting that Porcupine is responsible for this particular
lipidation. Whether Porcupine or a distinct acyltransferase is
involved inWNT3Apalmitoylationatcysteine77remains unknown.
Two additional proteins/protein complexes were identified for
Wg/Wnt secretion: Wntless (Wls), also known as Evenness inter-
rupted (Evi) or Sprinter (Srt), in Drosophila, and the retromer
complex in nematodes (Hausmann et al., 2007). Wls is a multi-
pass transmembrane protein that localizes to the Golgi, endo-
cytic compartments, and the plasma membrane, and is essential
for Wg secretion. The retromer complex, which is composed of
five subunits, was defined first in yeast. It mediates membrane
protein trafficking between endosomes and the Golgi apparatus
(Hausmann et al., 2007). Several groups recently reported that
the retromer complex is required for retrieval/recycling of Wls
from the endosome to the Golgi (Belenkaya et al., 2008;
Franch-Marro et al., 2008b; Pan et al., 2008a; Port et al., 2008;
Yang et al., 2008), which is likely mediated by direct interaction
between Wls and the retromer Vps35 subunit. Loss of retromer
function causes Wls to be degraded in the lysosomes and results
in reduction of Wls and thus Wnt secretion. These studies led to
an emerging picture of Wnt biogenesis (Figure 2). Wnt is glycosy-
lated and lipid modified by Porcupine in the ER, and is escorted
by Wls from the Golgi to the plasma membrane for secretion. Wls
is recycled by endocytosis and trafficked back to Golgi by the
retromer. Note that porc, wls, and retromer mutants largely phe-
nocopy wg/wnt mutants in flies and worms, attesting to their
dedicated roles in Wnt biogenesis.10 Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc.Caution is warranted, however, when the above model is
extrapolated to individual Wnt proteins. The effects of altering
the two lipid-modified residues on Wg secretion and function
are different from those on WNT3A (note the caveat that amino
acid substitutions may or may not fully mimic the effects of lack-
ing lipid adducts), leading to the suggestion that overall lipidation
levels may be more critical (Franch-Marro et al., 2008a). Differ-
ences in the order of glycosylation and lipidation also seem to
exist between WNT3A and Wg (Komekado et al., 2007; Tanaka
et al., 2002; Zhai et al., 2004). Lastly, Drosophila WntD neither
requires Porcupine and Wls for secretion nor is palmitoylated
at the conserved cysteine position (Ching et al., 2008).
Wnt Extracellular Distribution and Movement
Wnt proteins can function as morphogens that are capable of
both short- and long-range signaling, as best demonstrated for
Wg. Wg lipidation raises the issue of its diffusion and distribu-
tion through the aqueous extracellular space. Indeed, purified
WNT3A exhibits increased activity via artificial liposomal pack-
aging (Morrell et al., 2008). Two distinct Wg secretory pathways
for short- and long-range signaling have been speculated but not
fully substantiated. Wg may form multimers to bury lipid modifi-
cations inside (Katanaev et al., 2008) or bind to lipoprotein
particles that may be involved in Wg long-range signaling (Pan-
akova et al., 2005) (Figure 2). The membrane microdomain
protein reggie-1/flotillin-2 specifically promotes Wg long-range
secretion (Katanaev et al., 2008). The Wg receptors (see below)
and heparan sulfate proteoglycans (HSPGs) such as Dally and
Dally-like protein have important roles in the Wg morphogen
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endocytosis/transcytosis, and Dally and Dally-like may also
function in Wg signaling as potential low-affinity coreceptors
(Lin, 2004). Note that reggie-1/flotillin-2, lipoprotein particles,
and Dally and Dally-like protein are important analogously for
secreted Hedgehog morphogen, which is also lipid modified
(Katanaev et al., 2008; Lin, 2004; Panakova et al., 2005).
Wnt Receptors: Frizzled and LRP5/6
Two distinct receptor families are critical for Wnt/b-catenin
signaling (Figure 3): the Fz seven-pass transmembrane recep-
tors (Logan and Nusse, 2004) and LRP5/6 (He et al., 2004). The
Wnt-receptor relationship is best illustrated for Wg, which binds
toDrosophila Fz2 (Dfz2) and Dfz1 with high affinity (1–10 nM) and
requires either Fz in a redundant manner (Logan and Nusse,
2004). Wg reception also absolutely depends on Arrow, the
LRP5/6 homolog (He et al., 2004). The mammalian genome
harbors 10 Fz genes, most of which have variable capacities to
activate b-catenin signaling when co-overexpressed with Wnt
and LRP5/6 (e.g., Binnerts et al., 2007), and functional redun-
dancy among Fz members is likely prevalent (Logan and Nusse,
2004). Between the two LRPs, LRP6 plays a more dominant role
and is essential for embryogenesis, whereas LRP5 is dispens-
able for embryogenesis but critical for adult bone homeostasis.
Figure 2. Wnt Biogenesis and Secretion
Wnts are glycosylated and lipid modified in the ER, which involves Porcupine
and are escorted by Wntless from the Golgi to the plasma membrane for secre-
tion. Wntless is retrieved from endocytic vescicles and brought back to the
Golgi by the retromer complex. After secretion mature Wnts either bind to
HSPGs and lipoprotein particles or form multimers, which can modulate Wnt
gradients and facilitate long-range Wnt signaling. The numbers of Wnt mole-
cules bound to the lipoprotein particle and composed in multimeric form
were drawn arbitrarily.Nonetheless, LRP5 and LRP6 are partially redundant because
their functions together are required for mouse gastrulation (He
et al., 2004). Most data, including Wnt binding to LRP5/6,
WNT1-FZ8-LRP6 complex formation in vitro, and observations
that engineered Fz-LRP5/6 proximity is sufficient to activate
b-catenin signaling (Cong et al., 2004; Holmen et al., 2005; Tol-
winski et al., 2003), support the model that Wnt induces the
formation of Fz-LRP5/6 complex (He et al., 2004) (Figure 1).
But unambiguous demonstration of this receptor complex
in vivo is lacking. It is noteworthy that WNT3A palmitoylation
(at cysteine 77) is important for binding to both Fz and LRP6
(Cong et al., 2004; Komekado et al., 2007), explaining in part
the importance of this lipid modification.
A particular Wnt may activate b-catenin and/or noncanonical
pathways depending on the receptor complement (van Ameron-
gen et al., 2008). Fz function is involved in b-catenin and nonca-
nonical pathways. The Fz-LRP5/6 coreceptor model stipulates
that a Wnt-Fz pair capable of recruiting LRP5/6 activates the
b-catenin pathway, consistent with the specific requirement of
LRP5/6 in Wnt/b-catenin signaling (He et al., 2004). However,
some evidence suggests that LRP6 antagonizes noncanonical
Wnt signaling in vivo, possibly via competition for Wnt ligands
(Bryja et al., 2009) or an unknown mechanism (Tahinci et al.,
2007). Other Wnt receptors exist such as Ryk and ROR2, which
are not required for, but in some cases may antagonize, Wnt/
b-catenin signaling (van Amerongen et al., 2008).
Wnt Antagonists and Agonists
Several secreted protein families antagonize or modulate Wnt/
b-catenin signaling (Figure 3). Secreted Frizzled-related proteins
(sFRPs) and Wnt inhibitory protein (WIF) bind to Wnt, and in the
case of sFRPs, also to Fz (Figure 3), and thereby function as Wnt
antagonists for both b-catenin and noncanonical signaling
(Bovolenta et al., 2008). Loss-of-function studies in mice have
revealed significant redundancy for the sFRP genes (Satoh
et al., 2008). The Wnt-binding property suggests that sFRPs
and WIF may also regulate Wnt stability and diffusion/distribu-
tion extracellularly beyond just Wnt inhibitors. Some sFRPs
have been shown to act in Wnt-independent roles such as regu-
lators of extracellular proteinases (Bovolenta et al., 2008).
Two distinct classes of Wnt inhibitors are the Dickkopf
(DKK) family and the WISE/SOST family (Figure 3). DKK proteins,
exemplified by DKK1, are LRP5/6 ligands/antagonists and
are considered specific inhibitors of Wnt/b-catenin signaling.
Although two different models for DKK1 action have been
proposed (Mao et al., 2002; Semenov et al., 2001), recent
biochemical and genetic studies (Ellwanger et al., 2008; Seme-
nov et al., 2008; Wang et al., 2008) have argued against the model
that DKK1 inhibits Wnt signaling via inducing LRP6 internaliza-
tion/degradation through transmembrane Kremen (Krm) proteins
(Mao et al., 2002). DKK1 disruption of Wnt-induced Fz-LRP6
complex remains a more likely mechanism (Semenov et al.,
2001), with Krm playing a minor modulatory role in specific
tissues (Ellwanger et al., 2008). WISE and SOST constitute
another family of LRP5/6 ligands/antagonists (Itasaki et al.,
2003; Li et al., 2005; Semenov et al., 2005). Like DKK1, SOST is
able to disrupt Wnt-induced Fz-LRP6 complex in vitro (Semenov
et al., 2005). Both DKK1 and SOST are strongly implicated in
human diseases (see below).Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc. 11
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(A) Antagonists. WIF and sFRP bind directly to secreted Wnts and/or Fz. DKK and SOST/WISE proteins bind LRP5/6 to prevent Fz-LRP6 complex formation.
Shisa proteins trap Fz in the ER.
(B) Agonists. Wnts are the primary agonists and form a complex with LRP5/6 and Fz to activate signaling. Norrin acts similarly to Wnt, but binds specifically to
FZD4. R-spondin proteins (Rspo) act via and may bind to LRP5/6 and/or Fz receptors. In the ER, the chaperone MESD is needed for LRP5/6 maturation.Shisa proteins represent a distinct family of Wnt antagonists
(Figure 3) that trap Fz proteins in the ER and prevent Fz from
reaching the cell surface, thereby inhibiting Wnt signaling cell-
autonomously (Yamamoto et al., 2005). Shisa proteins also
antagonize fibroblast growth factor (FGF) signaling by trapping
FGF receptors in the ER. Other Wnt antagonists with multivalent
activities exist. Xenopus Cerberus binds to and inhibits Wnt as
well as Nodal and bone morphogenetic protein (BMP) (Piccolo
et al., 1999), and Insulin-like growth-factor (IGF) binding
protein-4 (IGFBP-4) antagonizes Wnt signaling via binding to
both Fz and LRP6, in addition to modulating IGF signaling (Zhu
et al., 2008).
Norrin and R-spondin (Rspo) proteins are two families of
agonists for Wnt/b-catenin signaling (Figure 3). Norrin is
a specific ligand for FZD4 and acts through FZD4 and LRP5/6
during retinal vascularization (Xu et al., 2004). Rspo proteins
exhibit synergy with Wnt, Fz, and LRP6 (Kazanskaya et al.,
2004; Kim et al., 2005; Nam et al., 2006; Wei et al., 2007), and
show genetic interaction with LRP6 during embryogenesis (Bell
et al., 2008), but their mechanism of action is controversial.
Results that Rspo binds to both Fz and LRP6 (Nam et al.,
2006), to LRP6 primarily (Wei et al., 2007), or to neither (Kazan-
skaya et al., 2004) have been reported. Another model suggests
that Rspo is a ligand for Krm and antagonizes DKK/Krm-medi-
ated LRP6 internalization (Binnerts et al., 2007), but this seems
unlikely given that Krm1 and Krm2 double knockout mice are
viable and do not exhibit Rspo mutant phenotypes, and that
Rspo activates b-catenin signaling in cells lacking both Krm
genes (Bell et al., 2008; Ellwanger et al., 2008). Rspo genes are
often coexpressed with, and depend on, Wnt for expression (Ka-
zanskaya et al., 2004), and may represent a means of positive
feedback that reinforces Wnt signaling. Mutations in Norrin and
Rspo genes cause distinct hereditary diseases (see below).12 Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc.Wnt Signaling
Wnt-off State: b-Catenin Phosphorylation/Degradation
by the Axin Complex
Cytosolic b-catenin phosphorylation/degradation and its regula-
tion by Wnt are the essence of Wnt signaling (Figure 1). The scaf-
folding protein Axin uses separate domains to interact with
GSK3, CK1a, and b-catenin, and coordinates sequential
phosphorylation of b-catenin at serine 45 by CK1a, and then at
threonine 41, serine 37, and serine 33 by GSK3 (Kimelman and
Xu, 2006). b-catenin phosphorylation at serine 33 and 37 creates
a binding site for the E3 ubiquitin ligase b-Trcp, leading to b-cat-
enin ubiquitination and degradation (Figure 4). Mutations of
b-catenin at and surrounding these serine and threonine resi-
dues are frequently found in cancers, generating mutant b-cate-
nin that escapes phosphorylation and degradation (Table 1).
Axin also contains a regulator of G protein signaling (RGS)
domain that interacts with APC, a large multifunctional scaf-
folding protein that binds b-catenin. These core Axin complex
components (Kimelman and Xu, 2006) share a common goal of
ensuring b-catenin phosphorylation and degradation. Indeed,
both APC and Axin are tumor suppressor genes, and APC muta-
tions are particularly prevalent in colorectal cancer (Table 1).
Several aspects of the Axin complex deserve further discus-
sion. (1) In addition to b-catenin, GSK3 and CK1 also phosphor-
ylate Axin and APC, leading to increased association of Axin
and APC with b-catenin, and thus, enhanced b-catenin phos-
phorylation/degradation (Huang and He, 2008; Kimelman and
Xu, 2006) (Figure 4). (2) Two abundant serine/threonine phospha-
tases, PP1 and PP2A, both of which associate with Axin and/or
APC, counteract the action of GSK3 and/or CK1 in the Axin
complex. Thus PP1 dephosphorylates Axin and promotes the
disassembly of the Axin complex (Luo et al., 2007), whereas
PP2A dephosphorylates b-catenin (Su et al., 2008), with each
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The core components of the Axin complex—Axin, APC, GSK3 and CK1—collectively promote b-catenin phosphorylation for degradation by b-Trcp. In addition to
phosphorylating b-catenin, GSK3 (yellow) and CK1 (blue) also phosphorylate Axin and APC and enhance their binding to b-catenin and degradation complex
stability, further ensuring b-catenin phosphorylation. The inset illustrates b-catenin phosphorylation (by CK1 and GSK3) and dephosphorylation (by PP2A).
APC may also act to prevent PP2A dephosphorylation of b-catenin. APC paradoxically facilitates Axin degradation and possibly vice versa (indicated by dashed
line, see text). PP1 dephosphorylates Axin to antagonize CK1 phosphorylation and negatively regulates GSK3-Axin binding, resulting in complex disassembly.dephosphorylation resulting in reduced b-catenin degradation
(Figure 4). One should note that PP2A may have multiple and
opposing roles in the Wnt pathway depending on the particular
associated regulatory subunits and substrates (Kimelman and
Xu, 2006). (3) The assembly of the Axin complex appears to be
multivalent and robust. In fly embryos that are null for Axin,
expression, at physiological levels, of Axin mutants lacking the
APC-, GSK3-, or b-catenin-binding domain restores a significant
degree of normal patterning, implying quasifunctional Axin
complex assembly via multivalent interactions; furthermore,
some of these Axin deletion mutants can complement each
other and restore fly viability, possibly via Axin dimerization or
multimerization (Peterson-Nedry et al., 2008). Indeed, Axin has
multiple potential dimerization domains (Luo et al., 2005) and
the Axin DIX domain may form multimeric polymers (Schwarz-
Romond et al., 2007a). (4) Axin concentration is exceedingly
low compared to other components in Xenopus oocytes, indi-
cating that Axin is rate limiting for the complex assembly. This
feature may ensure that changes in the Axin protein level will
not concomitantly affect the availability of GSK3 (or other
components) for non-Wnt functions, thereby further insulating
Wnt and other signaling events (Lee et al., 2003). It is unknown,
however, whether the drastic difference between the concentra-
tion of Axin versus the other components applies universally, and
whether different cells employ quantitative differences in the
ratio of Axin and other components to shape their unique Wnt
response kinetics (such as the speed and level of b-catenin
accumulation). Indeed, in Drosophila photoreceptors, APC
appears to be present at minimal levels such that a 50% reduc-
tion alters the graded Wg response (Benchabane et al., 2008).
Other proteins such as Wilms tumor gene on the X chromo-
some (WTX) may have roles in b-catenin degradation. Loss of
WTX and activating b-catenin mutations seem to have nonover-
lapping occurrence in Wilms tumor (a pediatric kidney cancer)
(Rivera et al., 2007). WTX binds to b-catenin, Axin, APC, and
b-Trcp to promote b-catenin ubiquitination, although itsbiochemical role remains unknown (Major et al., 2007). Another
Axin-binding protein, Diversin, can facilitate b-catenin degrada-
tion via recruiting CK13 to phosphorylate b-catenin (Schwarz-
Romond et al., 2002).
APC Function and APC-Axin Cross-Regulation
The biochemical nature of APC has been enigmatic. A recent
study suggested that APC protects b-catenin from dephosphor-
ylation by PP2A, thereby enhancing b-catenin phosphorylation/
degradation (Su et al., 2008) (Figure 4), consistent with the obser-
vation that Axin overexpression causes b-catenin degradation
even in cells lacking APC function (Behrens et al., 1998). Surpris-
ingly APC (upon phosphorylation by CK1/GSK3) and Axin bind to
and compete for the sameb-catenin interaction interface, leading
to a proposal that APC acts as a ‘‘ratchet’’ to remove phosphor-
ylated b-catenin from Axin for ubiquitination and for an increase in
Axin availability for a further round of b-catenin phosphorylation
(Kimelman and Xu, 2006; Xing et al., 2003). A different model
was proposed based on differential b-catenin binding affinity by
unphosphorylated versus phosphorylated APC (Ha et al., 2004).
APC has also been shown to promote b-catenin nuclear export
and to act as a chromatin-associated suppressor for b-catenin
target genes, thus functioning in the nucleus (see below).
Another paradoxical observation is that APC has a positive
function in physiological and ectopic Wg/Wnt signaling through
the promotion of Axin degradation (Lee et al., 2003; Takacs
et al., 2008) (Figure 4). One model suggests that this represents
a fail-safe mechanism to buffer dramatic b-catenin fluctuations
when APC levels vary (Lee et al., 2003). Thus a decrease in
the APC level results in higher Axin amounts, compensating
for b-catenin degradation. APC-mediated Axin degradation
depends on the APC amino terminal domain that is not involved
in b-catenin degradation (Takacs et al., 2008). It is intriguing that
colon cancer cells are rarely null for APC but do retain the amino
terminal half, suggesting that they may have hijacked a part of
this fail-safe regulation for tumorigenesis. Conversely, Axin can
also facilitate APC degradation upon overexpression (Choi et al.,Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc. 13
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Gene Function Human Disease References
PORCN + Wnt lipid modification/processing LOF X-linked Focal dermal hypoplasia Grzeschik et al., 2007; Wang et al., 2007
WNT3 + Ligand for Wnt/b-catenin signaling LOF tetra-amelia Niemann et al., 2004
WNT4 + Ligand for Wnt/b-catenin signaling LOF Mullerian-duct regression
and viriliation
Biason-Lauber et al., 2004
WNT5B + Ligand for Wnt/b-catenin signaling (?) type II diabetes Kanazawa et al., 2004
WNT7A + Ligand for Wnt/b-catenin signaling LOF Fuhrmann syndrome Woods et al., 2006
WNT10A + Ligand for Wnt/b-catenin signaling LOF odonto-onchyo-dermal hypoplasia Adaimy et al., 2007
WNT10B + Ligand for Wnt/b-catenin signaling LOF obesity Christodoulides et al., 2006
RSPO1 + Wnt agonist LOF XX sex reversal with palmoplantar
hyperkaratosis
Parma et al., 2006
RSPO4 + Wnt agonist LOF autosomal recessive anonychia
and hyponychia congenita
Bergmann et al., 2006;
Blaydon et al., 2006
SOST - LRP5/6 antagonist predominantly
expressed in osteocytes
LOF high bone mass, sclerosteosis,
Van Buchem disease
Balemans et al., 2001; Balemans et al.,
2002; Brunkow et al., 2001
Norrin
(NDP)
+ Specific ligand for FZD4 and LRP5
during eye development
LOF familial exudative
vitreoretinopathy
Xu et al., 2004
LRP5 + Wnt coreceptor GOF hyperparathyroid tumors (alt.
splicing), GOF high bone mass, LOF
osteoporosis-pseudoglioma, LOF
FEVR eye vascular defects
Bjorklund et al., 2007; Boyden et al.,
2002; Gong et al., 2001; Little et al.,
2002; Toomes et al., 2004
LRP6 + Wnt coreceptor LOF early coronary disease
and osteoporosis
Mani et al., 2007
FZD4 + Wnt receptor LOF familial exudative vitreoretinopathy Robitaille et al., 2002
Axin1  facilitates b-catenin degradation;
acts as a tumor suppressor
LOF caudal duplication, cancer Oates et al., 2006; Satoh et al., 2000
Axin2  facilitates b-catenin degradation;
acts as a tumor suppressor
LOF tooth agenesis, cancer Lammi et al., 2004; Liu et al., 2000
APC  facilitates b-catenin degradation;
acts as a tumor suppressor
LOF familial adenomatous
polyposis, cancer
Kinzler et al., 1991; Nishisho et al., 1991
WTX  facilitates b-catenin degradation;
acts as a tumor suppressor
LOF Wilms tumor Major et al., 2007; Rivera et al., 2007
b-catenin
(CTNNB1)
+ primary Wnt effector; acts as
anoncogene
GOF cancer Korinek et al., 1997; Morin et al., 1997
TCF4
(TCF7L2)
+ b-catenin transcriptional partner (?) type II diabetes Florez et al., 2006; Grant et al., 2006
LOF, loss-of-function; GOF, gain-of-function.2004), constituting perhaps the other side of the Axin-APC
regulation circuit (Figure 4). Mechanisms for Axin and APC
degradation, which are proteosome-dependent, have not been
characterized.
Wnt-on State: Activation of Wnt Receptors
Wnt signaling requires both Fz and LRP6 (or LRP5), likely
through a Wnt-induced Fz-LRP6 complex (Figure 1). Wnt-
induced LRP6 phosphorylation is a key event in receptor activa-
tion (Tamai et al., 2004). LRP6, LRP5, and Arrow each have five
reiterated PPPSPxS motifs (P, proline; S, serine or threonine, x,
a variable residue), which are essential for LRP6 function and
are each transferrable to a heterologous receptor to result in
constitutive b-catenin signaling (MacDonald et al., 2008; Tamai
et al., 2004; Zeng et al., 2005). These dually phosphorylated
PPPSPxS motifs are docking sites for the Axin complex (David-
son et al., 2005; Tamai et al., 2004; Zeng et al., 2005), thereby
recruiting Axin to LRP6 upon Wnt stimulation (Mao et al., 2001)
(Figure 5).14 Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc.The kinases responsible for PPPSPxS phosphorylation have
been identified unexpectedly as GSK3 and CK1 (Davidson
et al., 2005; Zeng et al., 2005). Although one study argued
that only CK1 phosphorylation is Wnt induced (Davidson et al.,
2005), most available data support that Wnt induces PPPSP
phosphorylation (Binnerts et al., 2007; Khan et al., 2007; Pan
et al., 2008b; Wei et al., 2007), which is carried out by GSK3
and primes xS phosphorylation by CK1, thereby leading to dually
induced phosphorylation (Zeng et al., 2005) (Figure 5). Although
potential involvement of additional kinases cannot be ruled
out, experiments in GSK3a/b null cells indicate that GSK3
accounts for most, if not all, PPPSP phosphorylation (Zeng
et al., 2005, 2008). As in b-catenin phosphorylation, Axin-bound
GSK3 appears to mediate LRP6 phosphorylation (Zeng et al.,
2008). Thus PPPSPxS phosphorylation exhibits a mirror image
of b-catenin phosphorylation in sequential order, in priming
requirement, and importantly, in functionality, but apparently
by the same Axin-GSK3 complex (Huang and He, 2008) (Figure 5).
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(A) Initiation and amplification. Wnt forms a complex with LRP6 and Fz-Dvl at the membrane. Dvl recruits Axin-GSK3, resulting in the phosphorylation of one or
more PPPSP motifs in LRP6 (initiation). Partially phosphorylated LRP6 may be able to recruit and more efficiently bind Axin-GSK3 and promote more PPPSP
phosphorylation (amplification).
(B) Signalsome formation via Dvl polymerization and receptor clustering. The oligiomerization property of Dvl promotes the aggregation of individual Wnt-LRP6-
Fz complexes, resulting in Axin recruitment to the membrane and LRP6 phosphorylation by GSK3 and CK1.
(C) PI4KIIa and PIP5KI kinases, the latter of which binds directly with Dvl and promote PIP2 production and receptor clustering/phosphorylation.
The configurations of receptor clustering in (B) and (C) were drawn arbitrarily. In all models, PPPSPxS motifs are sequentially phosphorylated by GSK3 and CK1,
probably via CK1g (membrane-associated) and/or CK1a and CK13 associated with Axin and Dvl, respectively, and MACF1 may have a role in the translocation of
the Axin complex to the receptors.This unusual mechanism, using the same kinase complex for
both positive and negative regulation, is reminiscent of another
morphogenetic pathway, Hedgehog signaling in Drosophila
(Price, 2006), and implies the simple view that Wnt signaling
regulates the two opposing activities of the Axin-GSK3 complex.One caveat is that GSK3 is genetically defined as a negative
regulator of b-catenin signaling. The positive requirement of
GSK3 in LRP6 activation is demonstrated when a membrane-
tethered GSK3 inhibitory peptide blocks Wnt signaling (Zeng
et al., 2008).Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc. 15
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and forced Fz-LRP6 association is sufficient to trigger LRP6
phosphorylation (Zeng et al., 2008). Fz function is usually linked
to Dsh/Dvl (Wallingford and Habas, 2005), a cytoplasmic scaf-
folding protein that may directly interact with Fz (Wong et al.,
2003). Indeed, Fz-Dvl interaction and Dvl function are critical
for Wnt-induced LRP6 phosphorylation (Bilic et al., 2007; Zeng
et al., 2008). Because Dvl interacts with Axin (Wallingford and
Habas, 2005), and is required for Axin recruitment to the plasma
membrane during Wg signaling (Cliffe et al., 2003) or in Fz over-
expression (Zeng et al., 2008), one model stipulates that Fz-Dvl
recruitment of the Axin-GSK3 complex initiates LRP6 phosphor-
ylation by GSK3 (Zeng et al., 2008) (Figure 5A).
Several features of Wnt receptor activation deserve further
discussion. (1) The observation that Axin is required for LRP6
phosphorylation, and that phosphorylated LRP6 in turn recruits
Axin, suggests a positive feedforward loop, potentially ampli-
fying and ensuring the phosphorylation of all five PPPSPxS
motifs (Figure 5). Indeed, the phosphorylation of these motifs
relies on the presence of one another, and LRP6 activity is partic-
ularly sensitive to the PPPSPxS copy number (MacDonald et al.,
2008; Wolf et al., 2008). This may explain the distinct roles of
Fz and LRP6/Arrow in the ‘‘initiation’’ (which requires both Fz
and Arrow) and ‘‘amplification’’ (which requires Arrow only)
during Wg signaling (Baig-Lewis et al., 2007) (Figure 5A). (2) It
has been reported that Wnt-induced clustering of Fz-LRP6
receptor critically depends on Dvl, Axin, and GSK3 for formation
(see below) (Bilic et al., 2007; Schwarz-Romond et al., 2007a).
Although unambiguous evidence for such aggregation under
physiological conditions without overexpression remains to be
demonstrated, this ‘‘signalsome’’ model (Figure 5B) and the
‘‘initiation-amplification’’ model (Figure 5A) together provide
a spatial and temporal framework for understanding Wnt
receptor activation. (3) Wnt also induces LRP6 phosphorylation
by CK1goutside the PPPSPxS motifs, in particular in a conserved
S/T cluster amino-terminal to the first PPPSPxS motif (Davidson
et al., 2005). This region upon phosphorylation binds to GSK3
(Piao et al., 2008), potentially accounting for the observed
LRP6-GSK3 interaction (Mi et al., 2006; Zeng et al., 2005). The
significance of this S/T cluster in LRP6 function has not been
investigated in the intact receptor, but these results imply multiple
interaction interfaces among LRP6, Axin, and GSK3. (4) Wnt may
also ‘‘activate’’ Fz, which is structurally related to G protein-
coupled receptors (GPCRs). Some genetic and pharmacological
evidence suggests that trimeric G proteins, specifically Gao and
Gaq, are required downstream of Fz and probably upstream of
Dvl in Wnt/b-catenin signaling (Katanaev et al., 2005; Liu et al.,
2001, 2005). Whether G proteins are involved in Wnt/Fz/Dvl-regu-
lated LRP6 phosphorylation is unknown.
Dvl is involved in Wnt/b-catenin and other Wnt/Fz-dependent
pathways and has numerous putative binding partners (Walling-
ford and Habas, 2005). For example, CK13 (or CK1d) binds to Dvl
and is a potent activator of b-catenin signaling, possibly via
phosphorylating Dvl, LRP6, and/or the Axin complex (Price,
2006) (Figure 5). PP2A also associates with Dvl but has a positive
or negative influence on Wnt signaling depending on the associ-
ated regulatory subunit (Kimelman and Xu, 2006). In addition, Dvl
is subjected to proteasomal degradation via distinct ubiquitina-
tion pathways (Angers et al., 2006; Simons et al., 2005). Some16 Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc.of these Dvl regulation events have been suggested to switch
Dvl between b-catenin and noncanonical pathways. Despite
this progress, the mechanism by which Dvl acts in Wnt/b-catenin
signaling remains enigmatic. Two recent findings suggest poten-
tial new insights. (1) Polymerization/aggregation of Dvl (and
Axin). Fz-Dvl and Dvl-Axin interactions are relatively weak
(Schwarz-Romond et al., 2007b; Wong et al., 2003). However,
Dvl and Axin each harbor a homologous DIX domain that exhibits
dynamic polymerization (Schwarz-Romond et al., 2007a). This
unusual property is proposed to allow Dvl and Axin to form large
aggregates that facilitate weak but dynamic protein interactions
(Figure 5B). Indeed, Wnt-induced receptor clustering requires an
intact Dvl DIX domain (Bilic et al., 2007; Schwarz-Romond et al.,
2007a). It is unclear whether Wnt regulates DIX-dependent
polymerization, and perhaps in a related manner, Fz-Dvl or
Dvl-Axin interaction. (2) Dvl stimulation of phosphatidylinositol
4,5-bisphosphate [PtdIns (4,5)P2 or PIP2] production by sequen-
tial actions of phosphatidylinositol 4-kinase type II (PI4KIIa)
and phosphatidylinositol-4-phosphate 5-kinase type I (PIP5KI)
(Pan et al., 2008b). Wnt induces Dvl, via the DIX domain, to
bind to and activate PIP5KI, and the resulting PIP2 production
is suggested to promote LRP6 clustering and phosphorylation,
although the underlying mechanism remains unclear (Figure 5C).
Given that PIP2 has pleiotropic functions in cells, including
receptor endocytosis (see below), other potential mechanisms
for PIP2 in LRP6 phosphorylation remain to be explored. None-
theless Dvl DIX polymerization and stimulation of PIP2 may act
in concert to ensure LRP6 clustering/phosphorylation/activation.
Other Regulatory Events at or proximal
to Wnt Receptors
A cytoplasmic protein in vertebrates, referred to as Caprin-2,
binds to LRP6 and facilitates LRP6 phosphorylation by GSK3
(Ding et al., 2008). Caprin-2 has an oligomerization domain that
may enhance LRP6 aggregation, and Caprin-2 additionally may
also associate with both GSK3 and Axin and promote LRP6-
Axin-GSK3 complex formation (Ding et al., 2008). Besides the
requirement of Dvl, recruitment of Axin to the receptor complex
may involve a giant protein (600 kD), microtubule actin cross-link-
ing factor 1 (MACF1) (Chen et al., 2006). MACF1 is a member of
the spectraplakin family of proteins that link the cytoskeleton to
junctional proteins. Defective gastrulation in Macf1/ mouse
embryos phenotypically resembles Lrp5/6/ double knockout
mutants. Upon Wnt stimulation MACF1 associates with the
Axin complex (including APC) in the cytosol and with LRP6
and the Axin complex (but not APC) in the membrane fraction
(Chen et al., 2006), and may shuttle Axin to LRP6 (Figure 5A).
This MACF1 function may be vertebrate specific because
DrosophilaMACF1 (shortstop) mutants do not exhibitwg-related
phenotypes.
A controversial issue concerns the involvement of receptor
endocytosis in Wnt signaling. Contradicting results have been re-
ported regarding the role of clathrin- and caveolin-dependent
receptor internalization and endosomal trafficking in Wnt receptor
activation and signaling (Gagliardi et al., 2008). For example, one
study suggested that caveolin-mediated LRP6 endocytosis
promotes Axin recruitment and is required for Wnt stabilization
of b-catenin (Yamamoto et al., 2006), whereas another study
using caveolin/ mutant mice reached the apparently opposite
conclusion (Sotgia et al., 2005). Pharmacological and molecular
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have pleiotropic and sometimes nonspecific effects, making
interpretations of some of these studies complicated.
Inhibition of b-Catenin Phosphorylation
How receptor activation leads to inhibition of b-catenin phos-
phorylation remains uncertain, and available data suggest
possible parallel mechanisms. In the LRP6-centric view,
because constitutively activated forms of LRP6 fully activate
b-catenin signaling in an apparently Fz- and Dvl-independent
manner (He et al., 2004), LRP6 represents the key output
whereas Fz and Dvl act upstream to control LRP6 activation
(Bilic et al., 2007; Zeng et al., 2008). On the other hand, Dsh over-
expression in Drosophila or recombinant Dvl in Xenopus egg
extracts can activate b-catenin signaling presumably in the
absence of Arrow/LRP6 (Salic et al., 2000; Wehrli et al., 2000),
and so does a GPCR-Fz chimeric protein in response to the
GPCR ligand (Liu et al., 2001). These results argue that Fz/Dvl
may activate b-catenin signaling independent of LRP6. The
fact that nematodes have a related Wnt/b-catenin pathway (Phil-
lips and Kimble, 2009), but have no LRP6 homolog, may be
consistent with this notion. Perhaps in Drosophila and verte-
brates, Wnt signaling components exist under suboptimal levels
and the two parallel branches need to operate together to coun-
teract efficient b-catenin phosphorylation/degradation, whereas
overactivation of either branch is sufficient to stabilize b-catenin.
Several biochemical mechanisms by which Wnt inhibits b-
catenin phosphorylation have been suggested (Kimelman and
Xu, 2006). (1) Wnt-induced and Dvl-(and Ga)-dependent Axin-
GSK3 (or b-catenin) dissociation (Liu et al., 2005; Logan and
Nusse, 2004). PP1 dephosphorylation of Axin also causes
Axin-GSK3 dissociation (Luo et al., 2007) (Figure 4), but whether
PP1 counteracts Axin complex assembly constitutively or is
regulated by Wnt is unknown. (2) Inhibition of GSK3. Phosphor-
ylated LRP6 cytoplasmic domain or individual phospho-
PPPSPxS peptides can directly inhibit GSK3 phosphorylation
of b-catenin in vitro (Cselenyi et al., 2008; Piao et al., 2008;
Wu et al., 2009), suggesting a potential mechanism for b-cate-
nin stabilization. This is consistent with the observation that
upon Wnt stimulation, dephosphorylated b-catenin first appears
at the plasma membrane close to activated LRP6 and Axin
(Hendriksen et al., 2008). (3) Axin degradation. Overexpression
of activated Wnt receptors or recombinant Dvl can lead to
Axin degradation (Lee et al., 2003; Mao et al., 2001; Tolwinski
et al., 2003), whereas GSK3 phosphorylation stabilizes Axin
(Willert et al., 1999; Yamamoto et al., 1999). However, Wnt-
induced Axin degradation lags significantly behind b-catenin
stabilization (Liu et al., 2005; Willert et al., 1999; Yamamoto
et al., 1999), and thus is unlikely to represent a primary response
despite its importance. Wnt signaling elevates APC protein
levels (Choi et al., 2004; Doble et al., 2007), but whether APC
accumulation is responsible for Wnt-induced Axin degradation
is unknown.
b-Catenin Nuclear Function
b-Catenin Nuclear/Cytoplasmic Shuttling and Retention
b-catenin stabilization results in its higher nuclear levels, but how
b-catenin is shuttled to and retained in the nucleus is not well
understood (Henderson and Fagotto, 2002; Stadeli et al.,
2006). Earlier studies suggested that b-catenin enters thenucleus in a nuclear localization signal (NLS)- and importin-inde-
pendent fashion by interacting directly with nuclear pore proteins
(Henderson and Fagotto, 2002). b-catenin also exits the nucleus
via export involving APC (Henderson and Fagotto, 2002), Axin
(Cong and Varmus, 2004), and Ran binding protein 3 (RanBP3),
which binds to b-catenin in a Ran-GTP-dependent manner (Hen-
driksen et al., 2005). Live cell imaging suggests that while Axin
and APC can enrich b-catenin in the cytoplasm, and while TCF
and b-catenin coactivators (BCL9 and Pygopus [Pygo]; see
below) increase nuclear b-catenin, they do not accelerate the
export or import rate of b-catenin, thereby arguing for their roles
in b-catenin retention rather than shuttling (Krieghoff et al., 2006).
Thus b-catenin nuclear and cytoplasmic partitioning is likely the
dynamic sum of both shuttling and retention between the two
compartments via multiple mechanisms.
A recent study argues that Wnt-induced b-catenin stabilization
is not sufficient for its nuclear accumulation, but Wnt activation of
the Rac1 GTPase is required in parallel (Wu et al., 2008). Specifi-
cally, Rac1, Jun N-terminal kinase 2 (JNK2), and b-catenin form
a cytoplasmic complex, and JNK2 phosphorylates b-catenin
(at serines 191 and 605) and promotes its nuclear translocation.
Other studies have suggested a role of Rac1 and its guanine
nucleotide exchange factors in b-catenin signaling, either as
components of the TCF/b-catenin transcriptional complex or
as an antagonistic partner of the Axin-APC complex (Esufali
and Bapat, 2004; Schlessinger et al., 2009). Further studies will
be required to clarify and substantiate whether and/or how Rac1,
which participates in noncanonical Wnt signaling, is involved in
the Wnt/b-catenin pathway.
TCF/LEF
The TCF/LEF family of DNA-bound transcription factors is the
main partner for b-catenin in gene regulation (Arce et al., 2006;
Hoppler and Kavanagh, 2007). TCF represses gene expression
by interacting with the repressor Groucho (TLE1 in human), which
promotes histone deacetylation and chromatin compaction;
Wnt-induced b-catenin stabilization and nuclear accumulation
leads TCF to complex with b-catenin, which appears to displace
Groucho (Daniels and Weis, 2005) and recruits other coactivators
for gene activation (Figure 1). While a single TCF gene is found in
Drosophila and worm, four TCF genes, TCF1, LEF1, TCF3, and
TCF4, exist in mammals. Alternative splicing and promoter usage
produce a large number of TCF variants with distinct properties
(Arce et al., 2006; Hoppler and Kavanagh, 2007). TCF proteins
are high-mobility group (HMG) DNA-binding factors, and upon
binding to a DNA consensus sequence referred to as the Wnt
responsive element (WRE), CCTTTGWW (W represents either
T or A), they cause significant DNA bending that may alter local
chromatin structure. A genome-wide analysis in colon cancer
cells suggests that TCF4/b-catenin target genes are frequently
‘‘decorated’’ with multiple WREs, most of which are located at
large distances from transcription start sites (Hatzis et al.,
2008). Some TCF1 and TCF4 splicing variants harbor a second
DNA-binding domain called C-clamp, which recognizes an
additional GC element downstream of the typical WRE, allowing
regulation of different sets of target genes (Atcha et al., 2007).
These similarities and differences, combined with overlapping
and unique expression patterns, underlie in part distinct and
sometimes redundant functions of vertebrate/mammalian TCF
genes. Note however that all major isoforms of the DrosophilaDevelopmental Cell 17, July 21, 2009 ª2009 Elsevier Inc. 17
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‘‘helper site’’ near the classic WRE, both of which together are
required to mediate most, if not all, Wg-responsive gene expres-
sion (Chang et al., 2008). Some general rules appear to describe
TCF/LEF functions approximately: TCF1 and TCF4 act as both
repressors and activators, and LEF1 is often an activator whereas
TCF3 is mostly a repressor but sometimes an activator (Arce
et al., 2006; Hoppler and Kavanagh, 2007).
Three major strategies exist to regulate TCF/b-catenin tran-
scription. (1) Alternative promoter usage in TCF1 and LEF1
genes produces dnTCF1/dnLEF1, which lack the amino-terminal
b-catenin-binding domain and thus act as the endogenous
dominant-negative TCF/LEF (Arce et al., 2006; Hoppler and
Kavanagh, 2007). Indeed, the TCF1 locus acts as an intestinal
tumor suppressor primarily due to the production of dnTCF1,
which antagonizes TCF4 in stem cell renewal. (2) Nuclear antag-
onists Chibby and ICAT bind to b-catenin and disrupt b-catenin/
TCF and b-catenin/coactivator interactions and promote b-cate-
nin nuclear export (Li et al., 2008; Tago et al., 2000). Besides
these devoted inhibitors, many DNA-binding transcription
factors interact with b-catenin or TCF and can antagonize TCF/
b-catenin-dependent transcription (Table S1). For example,
KLF4 inhibition of b-catenin transcriptional activation is impor-
tant for intestinal homeostasis and tumor suppression (Zhang
et al., 2006). (3) Posttranslational modifications of TCF/LEF
exist, including phosphorylation, acetylation, sumoylation, and
ubiquitination/degradation (Arce et al., 2006; Hoppler and Kava-
nagh, 2007; Phillips and Kimble, 2009, this issue). For instance,
TCF3 phosphorylation by CK13 and LEF1 phosphorylation by
CK2 enhances their binding to b-catenin and diminishes LEF1
binding to Groucho/TLE, whereas LEF1 and TCF4 phosphoryla-
tion by Nemo-like kinase (NLK) leads to less LEF/TCF/b-catenin
complex binding to DNA and leads to LEF1/TCF4 degradation.
LEF1 and TCF4 sumoylation (by the SUMO ligase PIASy)
represses LEF1 activity by targeting it to nuclear bodies but
enhances TCF4/b-catenin transcription, whereas CBP-mediated
acetylation of TCF results in decreased TCF/b-catenin binding in
Drosophila and increased TCF nuclear retention in nematodes,
Figure 6. Nuclear TCF/b-Catenin Coactivator Complexes
Upon Wnt/b-catenin signaling activation, WRE-bound TCF/b-cat-
enin recruits many coactivator complexes to Wnt target genes.
For simplicity only a few representative complexes are illustrated.
Dotted lines represent their interactions with b-catenin or between
complexes. During active Wnt target gene transcription, APC
promotes the exchange between b-catenin/coactivators with
corepressors CtBP, TLE, and HDAC in a cyclic manner (double-
headed red arrow) while TCF remains bound to the WRE. Ac
and Me symbolize histone modifications, i.e. acetylation and
methylation, respectively.
both leading to transcriptional repression. These
diverse modifications are often specific to individual
TCF/LEF proteins, conferring differential regulation. It
is unclear whether these TCF/LEF modifications are
controlled by Wnt or other signaling pathways in verte-
brates. Studies in nematodes have demonstrated that
Wnt directly regulates TCF phosphorylation (by NLK)
and therefore its nuclear export (in addition to b-catenin
stability), and the nuclear TCF:b-catenin ratio, intrigu-
ingly, may determine transcriptional activation versus repression
(Phillips and Kimble, 2009, this issue).
b-Catenin-Associated Coactivators
A plethora of b-catenin-associated coactivators have been identi-
fied. These multiproteincomplexes include BCL9 and Pygo, Medi-
ator (for transcription initiation), p300/CBP and TRRAP/TIP60
histone acetyltransferases (HATs), MLL1/2 histone methyltrans-
ferases (HMTs), the SWI/SNF family of ATPases for chromatin re-
modeling, and the PAF1 complex for transcription elongation and
histone modifications (Mosimann et al., 2009; Willert and Jones,
2006) (Figure 6). While the central Arm-repeats of b-catenin asso-
ciate with TCF, and the amino-terminal Arm-repeat binds to BCL9,
most of the coactivator complexes interact with the b-catenin
carboxyl terminal portion (Figure 6), creating a dazzling interplay
between b-catenin, the transcriptional apparatus, and the chro-
matin. Indeed, TCF/b-catenin binding to WREs leads to histone
acetylation in a CBP-dependent manner over a significant
genomic distance (30 kb), suggesting that local TCF/b-catenin
recruitment results in widespread chromatin modifications (Parker
et al., 2008). Histone H3K4 (lysine 4) trimethylation, which is indic-
ative of active transcription, is also observed at the WRE at the c-
Myc gene, a known Wnt target gene in some mammalian cells
(Sierra et al., 2006), but whether this is due directly to the recruit-
ment of HMTs by b-catenin or indirectly to reflect active promoter
usage remains to be established (Parker et al., 2008). Whether
various b-catenin-recruited coactivator complexes act simulta-
neously or in a particular sequential order remains unclear.
Intriguingly, under a Wnt-stimulated condition, while LEF1
occupies the WRE in the c-Myc gene continuously, b-catenin
and its coactivators cycle on and off the WRE with a 60 min peri-
odicity and are replaced by Groucho/TLE1 (Sierra et al., 2006;
Wang and Jones, 2006). Thus Groucho/TLE1 also acts as
a repressor during Wnt-responsive transcription. It is unknown
how the cyclic occupancy is governed and whether this cyclic
pattern between b-catenin/activators and Groucho/repressors
is integral to transcription of other Wnt-responsive genes, but
this dynamic exchange requires APC recruitment to chromatin
(Figure 6). These separate silencing (in the absence of Wnt)18 Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc.
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TLE1 may apply to other repressors such as CtBP, and may
help to explain different modes of CtBP repressor function that
have been described (Fang et al., 2006; Hamada and Bienz,
2004; Sierra et al., 2006). Curiously, CtBP (Fang et al., 2006)
and two related components of the SMRT/N-CoR corepressor
complex, TBL1 and TBLR1 (Li and Wang, 2008), are also b-cat-
enin coactivators for at least some Wg/Wnt-responsive genes.
In sum, both coactivator and corepressors appear to be active
during b-catenin-mediated transcription, perhaps ensuring a
dynamic chromatin environment for precise Wnt responses.
Unlike most coactivators that have general roles in transcrip-
tion, BCL9 and Pygo in Drosophila are specifically required for
b-catenin-dependent transcription and their biochemical func-
tions proposed provide a glimpse of the complexity of TCF/b-cat-
enin-coactivator interactions (Mosimann et al., 2009). (1) BCL9
and Pygo function as a ‘‘chain of activators’’ (Hoffmans et al.,
2005). b-catenin binding to BCL9 recruits Pygo, which also inter-
acts with Mediator (Carrera et al., 2008) (Figure 6); (2) Pygo is
constitutively nuclear and may have a role in recruiting/retaining
BCL9/b-catenin in the nucleus upon Wg/Wnt signaling (Brem-
beck et al., 2004; Townsley et al., 2004); (3) Pygo also co-occu-
pies chromatin loci with and via TCF in the absence of Wg
signaling (despite a lack of direct TCF-Pygo interaction), and
may help capture BCL9/b-catenin for TCF at the onset of Wg
signaling (de la Roche and Bienz, 2007); and (4) Pygo has a plant
homology domain (PHD) that binds preferentially to dimethylated
H3K4 upon interaction with BCL9 (Fiedler et al., 2008). This
‘‘histone code’’ recognition leads to the speculation that Pygo/
BCL9 act during the transition from gene silencing to Wnt-
induced transcription by participating in histone methylation
changes. Alternatively, Pygo/BCL9 binding to dimethylated
H3K4 may provide a separate b-catenin anchor on chromatin,
thereby freeing TCF for interaction with Groucho to pause or
terminate transcription (Mosimann et al., 2009). Finally, (5) Pygo
function is not required when Groucho activity is absent, suggest-
ing that Pygo acts as an antirepressor (Mieszczanek et al., 2008).
Therefore, either a single biochemical mechanism of Pygo under-
lies these diverse observations, or multiple functional properties
of Pygo participate in b-catenin signaling. Perplexingly, however,
Pygo function is not as critical for Wnt/b-catenin signaling in mice,
because Pygo1 and Pygo2 double mutants exhibit significantly
milder phenotypes than expected (Schwab et al., 2007), possibly
reflecting Pygo’s redundancy with other coactivators. Mamma-
lian BCL9 function has also diverged compared to that in
Drosophila, and exhibits cell-type-specific and Pygo-indepen-
dent roles in modulating Wnt signaling (Sustmann et al., 2008).
Nuclear Functions of ‘‘Cytoplasmic’’ Wnt Signaling
Components
APC also acts directly on chromatin/WREs to antagonize b-cate-
nin-mediated gene activation via promoting the exchange of
coactivators with corepressors in a stepwise and oscillating
manner, because such exchange does not occur in APC mutant
cancer cells (Sierra et al., 2006). How APC is recruited to chro-
matin is a mystery, but it is unlikely due to b-catenin/TCF,
because APC and TCF bind to b-catenin in a mutually exclusive
manner. GSK3 and b-Trcp also appear to be associated with
the WRE in a cyclic fashion that synchronizes with APC but is
opposite to that of b-catenin/coactivators, suggesting that theymay have negative roles in TCF/b-catenin-mediated transcription
(Sierra et al., 2006). Some studies have also suggested that Dvl is
observed in the nucleus (Itoh et al., 2005; Torres and Nelson,
2000) and that nuclear Dvl is a component of the TCF/b-catenin
complex and facilitates TCF/b-catenin interaction in conjunction
with the c-Jun transcription factor (Gan et al., 2008). While
provocative, some of these findings require substantiation and,
in particular, reconciliation with (the lack of) genetic evidence.
Nonetheless, the proposed nuclear functions for Dvl, APC, and
perhaps GSK3 and b-Trcp in the TCF/b-catenin complex are in
sync with their cytoplasmic functions in regulation of b-catenin
stability (i.e., to either promote or inhibit b-catenin signaling).
b-Catenin-Mediated Repression and Other
Transcriptional Events
Wnt signaling, via the TCF/b-catenin complex, also represses
transcription of certain target genes. Note that this is distinct
from TCF-mediated repression in the absence of b-catenin.
One mechanism is competitive repression, through which TCF/
b-catenin displaces or inhibits other DNA-binding transcription
activators (Kahler and Westendorf, 2003; Piepenburg et al.,
2000). Another mechanism is direct repression via TCF/b-cate-
nin binding to the canonical WREs by recruiting corepressors
(Jamora et al., 2003; Theisen et al., 2007). A third mechanism
is revealed by a novel TCF binding element, AGAWAW, which
specifically mediates TCF/b-catenin repression in Drosophila
(Blauwkamp et al., 2008). There is evidence that b-catenin is
capable of recruiting corepressors including Groucho/TLE and
histone deacetylases (Olson et al., 2006), but the mechanism
by which b-catenin recruits coactivators versus corepressors is
unknown. The involvement of cofactors (Theisen et al., 2007)
or distinct TCF/b-catenin configurations offers potential expla-
nations. A less understood aspect of b-catenin signaling is that
many DNA-binding transcription factors, in addition to TCF/
LEF, interact with b-catenin to either activate or repress tran-
scription (Table S1B). These b-catenin partners in principle
expand significantly the gene expression programs that are
regulated by Wnt/b-catenin signaling, but further substantiation
of their roles in mediating Wnt signaling is required.
Wnt/b-Catenin Target Genes and Wnt Pathway
Self-Regulation
Because Wnt/b-catenin signaling regulates proliferation, fate
specification, and differentiation in numerous developmental
stages and adult tissue homeostasis, Wnt target genes are
diverse (Vlad et al., 2008) and cell and context specific (Logan
and Nusse, 2004). An emerging feature is that Wnt signaling
components, including Fz, LRP6, Axin2, TCF/LEF, Naked (a Dvl
antagonist), DKK1, and Rspo, are often regulated positively or
negatively by TCF/b-catenin (Chamorro et al., 2005; Kazanskaya
et al., 2004; Khan et al., 2007; Logan and Nusse, 2004). Wnt
induction of Axin2, DKK1, and Naked and suppression of Fz
and LRP6 constitute negative feedback loops that dampen Wnt
signaling, and the suppression of Fz and LRP6 also enhances
Wg/Wnt gradient formation over longer distances (Logan and
Nusse, 2004). On the contrary, Wnt induction of Rspo and TCF/
LEF genes constitutes positive feedforward circuits that reinforce
Wnt signaling, a feature that has been exploited during colon
carcinogenesis (Arce et al., 2006; Hoppler and Kavanagh,
2007). These various Wnt pathway self-regulatory loops are
mostly utilized in a cell-specific manner, affording additionalDevelopmental Cell 17, July 21, 2009 ª2009 Elsevier Inc. 19
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responses. However, Axin2 and Drosophila Naked genes seem
to represent a few ‘‘universal’’ Wnt/Wg-induced target genes,
respectively (Logan and Nusse, 2004).
Wnt/b-Catenin Signaling in Diseases and Potential
Therapeutics
Given the critical roles of Wnt/b-catenin signaling in development
and homeostasis, it is no surprise that mutations of the Wnt
pathway components are associated with many hereditary disor-
ders, cancer, and other diseases (Table 1). These include muta-
tions in Porcupine (PORCN in human) and various Wnt ligands,
agonists, and antagonists, and have shed light on Wnt regulation
of human development. For example, RSPO1 mutations result in
XX sex reversal (Parma et al., 2006), a condition with similarities
to patients with WNT4 mutations (Biason-Lauber et al., 2004),
which is consistent with cooperation between Rspo and Wnt
genes. Mutations in either FZD4 or LRP5 are associated with
familial exudative vitreoretinopathy (FEVR) (Toomes et al., 2004),
which is manifested by defective retinal vascularization that is
also seen in Norrie-disease-carrying Norrin mutations, leading to
the identification of Norrin as a ligand for FZD4 and LRP5 (Xu
et al., 2004).
One fast-growing field involves Wnt/b-catenin regulation of
bone mass, because osteoporosis remains a global health
problem. This was triggered by the discovery of LRP5 loss-of-
function mutations in patients with osteoporosis pseudoglioma
syndrome (OPPG), a recessive disorder characterized by low
bone mass and abnormal eye vasculature (Gong et al., 2001).
Conversely, patients with autosomal dominant high bone mass
(HBM) diseases harbor LRP5 missense (gain-of-function) muta-
tions (Boyden et al., 2002; Little et al., 2002), which are clustered
in the LRP5 extracellular domain and render LRP5 resistant
to binding and inhibition by the antagonist SOST (Ellies et al.,
2006; Semenov and He, 2006) and DKK1 (Ai et al., 2005). Interest-
ingly, mutations in the SOST gene cause Sclerosteosis (Table 1),
which resembles HBM disorders. Thus LRP5 activity likely corre-
lates with bone mass via regulation of osteoblast (bone-forming
cell) proliferation, whereas SOST and DKK1, which are specifi-
cally expressed in osteocytes, negatively regulate bone mass
by antagonizing LRP5. Given that reduction of sFRP1 or DKK1
also results in increased bone mass in mice, secreted Wnt antag-
onists have become important drug targets for the treatment of
osteoporosis (Williams and Insogna, 2008). Indeed, humanized
antibodies against SOST and a small molecule antagonist
against sFRP1 are being tested, and both showed promise in
increasing bone mass (Bodine et al., 2009). Antibodies against
DKK1 have also been used to treat mouse models of multiple
myeloma (Yaccoby et al., 2007) and osteoarthritis (Diarra et al.,
2007), both of which are associated with bone tissue loss.
Because LRP6 also acts as a coreceptor for parathyroid hormone
(PTH) (Wan et al., 2008), which is used as a drug for osteoporosis,
and because a new model for LRP5 function in bone mass regu-
lation via an endocrine route (through serotonin) has recently
been proposed (Yadav et al., 2008), interest in the roles of
LRP5, LRP6, and their agonists and antagonists in bone homeo-
stasis will continue to grow. Such interest likely extends to other
metabolic disorders because LRP6 mutation is also linked to
coronary artery disease (Mani et al., 2007) (Table 1).20 Developmental Cell 17, July 21, 2009 ª2009 Elsevier Inc.TCF7L2 (i.e., TCF4) is strongly implicated in type II diabetes
(Grant et al., 2006), echoing the implication of WNT5B in the
disease (Table 1). Although the diabetes-associated TCF7L2
gene polymorphism does not alter protein coding (because it
occurs in intron 4) and its exact molecular nature (i.e., reduction
or increase in TCF7L2 function) is unclear, its association with
the disease has been confirmed in numerous populations
(Welters and Kulkarni, 2008). Some studies have suggested
that the predisposing TCF7L2 variant causes a decrease in
insulin secretion in insulin-producing pancreatic b cells, but other
pathogenic mechanisms involving additional tissues/organs or
endocrine functions remain to be investigated.
Association of deregulated Wnt/b-catenin signaling with
cancer has been well documented, particularly with colorectal
cancer (Polakis, 2007) (Table 1). Constitutively activated b-cate-
nin signaling, due to APC deficiency or b-catenin mutations that
prevent its degradation, leads to excessive stem cell renewal/
proliferation that predisposes cells to tumorigenesis. Indeed,
APC deletion or b-catenin activation in stem cells is essential
for intestinal neoplasia (Fuchs, 2009). Blocking b-catenin signal-
ing as a cancer treatment has therefore generated significant
interest. In fact, the beneficial effect of nonsteroidal anti-inflam-
matory drugs (NSAIDS) in colorectal cancer prevention and
therapy has been attributed partially to the perturbation of
TCF/b-catenin signaling through the ability of NSAIDS to inhibit
Prostaglandin E2 production, which enhances TCF/b-catenin-
dependent transcription (Castellone et al., 2005; Shao et al.,
2005). Small molecules that disrupt TCF/b-catenin (Lepourcelet
et al., 2004) or b-catenin/coactivator (CBP) interaction (Emami
et al., 2004) and thereby block TCF/b-catenin signaling have
been described. The task of disrupting TCF/b-catenin interaction
specifically, however, is a difficult one because b-catenin inter-
acts with TCF and other binding partners such as APC, Axin,
and E-cadherin via the same or an overlapping interface (Barker
and Clevers, 2006). Another potential therapeutic target is the
kinase CDK8, which, as a Mediator subunit, is often amplified
in and is required for b-catenin-dependent transcription and
proliferation of colon cancer cells (Firestein et al., 2008; Morris
et al., 2008). A new class of small molecules that inhibits b-cate-
nin signaling has recently be identified (Chen et al., 2009), which
via an unknown mechanism stabilizes the Axin protein, thereby
promoting b-catenin degradation even in cancer cells that lack
APC function. As discussed above, since Axin protein levels
are the rate-limiting step for b-catenin degradation, manipulation
of Axin stabilization represents a promising therapeutic strategy.
Many cancers that do not harbor mutations in the Wnt
pathway nonetheless rely on autocrine Wnt signaling for prolifer-
ation or survival (Barker and Clevers, 2006). In fact APC mutant
colon cancer cells maintain their dependence on Wnt and epige-
netically silence the expression of secreted Wnt antagonists
(He et al., 2005; Suzuki et al., 2004). Therefore targeting Wnt
signaling upstream of TCF/b-catenin is also an important thera-
peutic option. Reagents against Wnt proteins such as antibodies
(He et al., 2005) or secreted Fz extracellular domains (DeAlmeida
et al., 2007), which act outside the cancer cells to block
Wnt-receptor interaction, show promise in certain experimental
settings, as do small molecule and peptide inhibitors that antag-
onize Fz-Dvl interaction (Shan et al., 2005; Zhang et al., 2009).
Small molecules have also been identified that inhibit Porcupine
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Reviewand thus prevent Wnt lipidation and secretion (Chen et al., 2009).
We will likely see additional molecular and chemical agents that
can interfere with different steps of Wnt/b-catenin signaling,
whose complexity presents many potential therapeutic targets.
The challenge will be ensuring that these agents target cancer
cells without damaging normal tissue homeostasis.
Perspectives
Since the discovery of the WNT1 gene 27 years ago (Nusse and
Varmus, 1982), Wnt/b-catenin signaling has cemented its role
as a key regulatory system in biology. Studies of different animal
models and human diseases have established a complex Wnt
signaling network far beyond a linear pathway, with many
components having multiple distinct roles and acting in different
cellular compartments, and many modulators feeding into and
cross-regulating within this network. The patterns of dynamic
and kinetic protein phosphorylation/modification and complex
assembly/disassembly are beginning to emerge. Challenges
and excitement both lie ahead. (1) Novel regulators will likely
continue to be identified using classical genetic, molecular, and
modern genomic and proteomic approaches. (2) New analytical
and imaging technologies should enable us to dissect and visu-
alize the dynamic signaling events in vivo and to shed light on
the cell biological aspects of Wnt signaling, including where,
when, and how signaling occurs inside the cell. (3) Although we
have obtained significant structural information on individual
domains and protein interaction interfaces, atomic structures of
protein complexes such as the Axin complex and ligand-receptor
complexes remain daunting challenges. (4) Additional specific
small molecular inhibitors or activators with defined targets and
mechanisms would provide not only leads for therapeutics but
also research tools to manipulate the Wnt pathway in precise
temporal and spatial manners. (5) Integration of vast amounts
of information into quantitative models will allow us to predict
the behavior and to study the robustness and evolvability of
Wnt signaling in various biological contexts. (6) The Wnt-respon-
sive transcriptome remains a gold mine in which we should dig for
answers surrounding Wnt-regulated biology. Unfolding exam-
ples include Wnt regulation of intestinal and hair follicle develop-
ment/homeostasis, which has provided significant insights into
stem cell biology and cancer pathogenesis (Clevers, 2006;
Fuchs, 2009). Because b-catenin is a coactivator for other tran-
scription factors in addition to TCF/LEF, comparative analyses
of Wnt-responsive transcription programs that depend on TCF/
LEF versus others will likely uncover further complexity in Wnt-
regulated gene expression. (7) b-catenin and APC are also key
components in the E-cadherin cell adhesion complex and the
microtubule network, but how Wnt/b-catenin signaling interacts
with these cellular structures remains poorly understood. In addi-
tion, the involvement of the primary cilium, a centrosome- and
microtubule-based protrusive organelle in vertebrate cells, in
Wnt/b-catenin versus noncanonical Wnt signaling remains an
intriguing but debated topic (Gerdes et al., 2009).
Finally, the study of Wnt signaling in human diseases, and in
stem cell biology and regeneration, holds promises for transla-
tional medicine. In addition to cancer and osteoporosis, both
of which will likely see Wnt-signaling-based therapeutics moving
into clinical trials or even clinics in the near future, potential links
between neurological diseases (De Ferrari and Moon, 2006) anda schizophrenia susceptibility gene product (Mao et al., 2009) to
Wnt/b-catenin signaling offer new hopes for the treatment of
neurological and psychiatric disorders. Manipulation of Wnt
signaling for stem cell regulation also offers exciting opportuni-
ties for regenerative medicine (Clevers, 2006; Fuchs, 2009;
Goessling et al., 2009; Willert et al., 2003). A better under-
standing of Wnt/b-catenin signaling will have a broad impact
on biology and medicine.
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